Literature DB >> 3829001

Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.

P J Houghton, J A Houghton, G Germain, P M Torrance.   

Abstract

In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed. A cell line (GC3/M) was established in continuous culture that demonstrated a karyotype identical to that of the stem line of H X GC3 (46,X, - Y + 12). After inoculation of GC3/M cells into immune-deprived CBA/CaJ mice, the H X GC3/M xenografts retained histological, histochemical, and growth characteristics of the H X GC3 xenograft. To develop a line deficient in dThd salvage, GC3/M cells were selected with BrdUrd (100 micrograms/ml). Three clones characterized were unable to proliferate in HAT medium, and were deficient (less than 10% control) in the cytosolic form of thymidine kinase. Activities of dThd phosphorylase and dTMP synthase were unchanged from parental GC3/M cells. Of the three clones inoculated into mice, GC3/M TK- 100 C3 was tumorigenic, the xenografts demonstrating histological and growth characteristics similar to H X GC3. The in vivo activity of the cytosolic form of dThd kinase was 3.5% of that in H X GC3 xenografts. Incorporation in vivo of [methyl-3H]dThd into acid insoluble material was 14% of that in H X GC3 tumors. Autoradiographs prepared from these tumors demonstrated that incorporation of radiolabel into nuclei occurred only in stromal cells derived from the host. It is anticipated that H X GC3/M TK- 100 C3 will be a line valuable for determining the role of dThd salvage in intrinsic resistance to 5-fluoropyrimidines or antifolates in human colon adenocarcinomas growing as xenografts and also the relevance of dTMp synthase as a target for antimetabolites in this histiotype.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829001

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.

Authors:  P J Houghton; G S Germain; B J Hazelton; J W Pennington; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 2.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

3.  Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.

Authors:  B Chandrasekaran; T E Kute; D S Duch
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 4.  Role of pH in Regulating Cancer Pyrimidine Synthesis.

Authors:  Saad Saeed Alqahtani; Tomas Koltai; Muntaser E Ibrahim; Adil H H Bashir; Sari T S Alhoufie; Samrein B M Ahmed; Daria Di Molfetta; Tiago M A Carvalho; Rosa Angela Cardone; Stephan Joel Reshkin; Abdelhameed Hifny; Mohamed E Ahmed; Khalid Omer Alfarouk
Journal:  J Xenobiot       Date:  2022-07-06

5.  Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity.

Authors:  Shao-yu Wu; Tian-min Chen; William H Gmeiner; Edward Chu; John C Schmitz
Journal:  Nucleic Acids Res       Date:  2013-02-28       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.